Licensing

MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner

July 19, 2018

Exclusive global license agreement with Novartis on MOR106 MOR106, a monoclonal antibody directed against IL-17C, will be developed further in atopic dermatitis (AtD) and potentially other indications Up-front payment of EUR 95 million (USD 111 million*) and potential milestone payments of up to approximately EUR 850 million (USD 1 billion*) plus royalties up to low-teens […]

APAC Biotech and Diakonos Sign Technology Transfer and Licensing Agreement to Bring New Immunotherapy Technology to India

June 22, 2018

HOUSTON, June 22, 2018 /PRNewswire/ — India-Based APAC Biotech and US-Based Diakonos Research sign a first-of-its-kind technology transfer and licensing agreement to bring new immunotherapy technology to India as an advancement of immuno-oncology therapeutics for solid tumors. (Logo: http://mma.prnewswire.com/media/486747/APAC_Biotech_Logo.jpg ) This new path breaking technology effectively targets and activates the tumor antigen specific CTL-response and […]

MaaT Pharma and Lutech Sign Licensing Agreement on Microbiome Therapy for Graft-vs-Host Disease

June 21, 2018

Lyon, France, June 21, 2018 – MaaT Pharma, a clinical-stage microbiome therapy company, and SATT Lutech, a private technology transfer company holding the exclusive rights to the scientific findings from research groups at Sorbonne University, APHP, CNRS and INSERM, today announced a licensing agreement under which MaaT Pharma will receive world-wide exclusive rights for the […]

NeuroVive Out-licenses Targeted LHON Therapy to BridgeBio Pharma’s New Subsidiary Fortify Therapeutics

June 19, 2018

LUND, Sweden and PALO ALTO, Calif., June 19, 2018 /PRNewswire/ — NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and BridgeBio Pharma today jointly announced that BridgeBio has entered into an exclusive licensing agreement for a subset of succinate prodrug chemistry under NeuroVive’s NVP015 program. BridgeBio also announced that it has launched a subsidiary company […]

Pacira Pharmaceuticals and Nuance Biotech Announce License Agreement for EXPAREL® in China

June 19, 2018

PARSIPPANY, N.J. and SHANGHAI, China, June 19, 2018 (GLOBE NEWSWIRE) — Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) and Nuance Biotech Co. Ltd (Nuance) today announced that they have entered into an agreement with Nuance, a China based specialty pharmaceutical company, to advance the development and commercialization of EXPAREL® (bupivacaine liposome injectable suspension) in China. EXPAREL is a […]

Aptose Enters Into License Agreement With CrystalGenomics to Acquire CG-806 Rights in China

June 14, 2018

SAN DIEGO and SEOUL, South Korea, June 14, 2018 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) today announced that they have entered into a license agreement with CrystalGenomics, Inc. (KOSDAQ:083790) for China rights to CG-806 (including People’s Republic of China, Hong Kong and Macau). Aptose will now own worldwide rights (excluding Korea) to develop […]

Arsanis Out-Licenses Preclinical Stage Klebsiella pneumoniae Monoclonal Antibodies from ASN300 Program

June 14, 2018

WALTHAM, Mass. and VIENNA, Austria, June 14, 2018 (GLOBE NEWSWIRE) — Arsanis, Inc. (NASDAQ:ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today announced that it has entered into an agreement under which BB200, LLC, a portfolio company of Bravos Biosciences, LLC, has secured an exclusive, worldwide preclinical […]

Nkarta Therapeutics Announces Exclusive License to Natural Killer Cell Technology From National University of Singapore and St. Jude Children’s Research Hospital

June 11, 2018

SOUTH SAN FRANCISCO, Calif., June 11, 2018 (GLOBE NEWSWIRE) — Nkarta Therapeutics, a privately-held cell therapy company developing Natural Killer (NK) immune cells to fight cancer, today announced that it has entered into a worldwide exclusive license agreement for proprietary Natural Killer cell engineering technology jointly owned by the National University of Singapore (NUS) and […]

Axovant Licenses Investigational Gene Therapy for Parkinson’s Disease from Oxford BioMedica and Announces Key Leadership Team Addition

June 6, 2018

BASEL, Switzerland, June 06, 2018 (GLOBE NEWSWIRE) — Axovant Sciences (NASDAQ:AXON) today announced that it has licensed the exclusive worldwide rights to develop and commercialize OXB-102, now AXO-Lenti-PD, from Oxford BioMedica. AXO-Lenti-PD is an investigational gene therapy for Parkinson’s disease that delivers three genes encoding a critical set of enzymes required for dopamine synthesis in […]

Verastem Oncology and Yakult Honsha Co., Ltd. Sign Exclusive License Agreement for the Development and Commercialization of Duvelisib in Japan

June 5, 2018

BOSTON & TOKYO–(BUSINESS WIRE)–Verastem, Inc. (President and CEO: Robert Forrester)(NASDAQ:VSTM) and Yakult Honsha Co., Ltd. (President: Takashige Negishi)(Tokyo:2267), today announced their entry into an exclusive licensing agreement for Yakult to develop and commercialize Verastem’s duvelisib, a first-in-class oral dual inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma, for the treatment, prevention or diagnosis of all oncology […]

Denovo Biopharma Acquires Exclusive License of Novel Application of DB102 in the Treatment of Pulmonary Arterial Hypertension

June 4, 2018

SAN DIEGO, June 4, 2018 /PRNewswire/ — Denovo Biopharma LLC, a pioneer in using precision medicine to develop innovative therapies, today announced it has entered into an exclusive global license agreement with the Stanford University School of Medicine that will enable Denovo to develop and commercialize its lead compound, enzastaurin (DB102), in treating pulmonary arterial […]

Harbour BioMed Announces Multi-Year Transgenic Platform Licensing Agreement with Celsius Therapeutics for Fully Human Monoclonal Antibody Drug Discovery

June 1, 2018

SHANGHAI & ROTTERDAM, Netherlands & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Harbour BioMed announced today that it has licensed its patented H2L2 fully human antibody discovery platform to Celsius Therapeutics, a newly launched company translating single-cell genomic insights into precision therapeutics. The license was issued through Harbour BioMed’s wholly owned subsidiary, Harbour Antibodies BV.   “Therapeutic antibody discovery is […]

BioIVT Granted Human Tissue Authority License for a Second UK Site

May 31, 2018

HTA licenses help verify that BioIVT biospecimens meet the highest quality standards.   BioIVT, a leading provider of biospecimens and related services, today announced that the Human Tissue Authority (HTA) has granted a satellite license to its West Sussex facility.   “Our goal is to always provide our customers with the highest quality biospecimens and […]

Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Enter into Ex-U.S. Licensing Agreement to Commercialize KORSUVA™ Injection in Dialysis Patients with Pruritus

May 23, 2018

STAMFORD, Conn., May 23, 2018 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq:CARA), a U.S. biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced that it has licensed worldwide rights, except in the U.S., Japan and South Korea, to commercialize […]

Eiger Announces Expanded License Agreement with Merck for Investigational Candidate Lonafarnib and Collaboration with The Progeria Research Foundation (PRF)

May 22, 2018

– Plans to Seek FDA Guidance for Potential Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) Indication PALO ALTO, Calif., May 16, 2018 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that it has expanded its licensing agreement with Merck, known as MSD outside […]

Mundipharma and Endoceutics to Exclusively License Intrarosa™ (Prasterone) in MEA Region

May 21, 2018

DUBAI, UAE, May 20, 2018 /PRNewswire/ — A unique non-estrogen prescription therapy, Intrarosa™, has been approved by the US Food and Drug Administration (FDA) and by the European Medical Agency (EMA), for the treatment of the most bothersome symptom of vulvovaginal atrophy, due to menopause, known as dyspareunia. Mundipharma has been granted the commercial rights […]

Fate Therapeutics and Memorial Sloan Kettering Cancer Center Expand Scope of License Agreement to include Gene-edited T-cell Immunotherapies

May 16, 2018

SAN DIEGO, May 16, 2018 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today the Company has gained access to additional intellectual property from Memorial Sloan Kettering Cancer Center (MSK) that enables the development of gene-edited T-cell immunotherapies. […]

UTILITY therapeutics signs license agreement with LEO Pharma A/S for US rights to mecillinam and pivmecillinam

May 15, 2018

London, UK. 15th May 2018 – UTILITY therapeutics Ltd (“UTILITY” or “the Company”), a pharmaceutical company focused on developing and commercialising antibiotics in the US, today announces the signature of an exclusive license agreement for the antibiotics mecillinam and pivmecillinam with LEO Pharma A/S. The license agreement provides UTILITY with exclusive access to LEO Pharma’s […]

Two Labs Hires Anita Dopkosky as Vice President of Specialty Pharmacy

May 10, 2018

FOR IMMEDIATE RELEASE Media Contact: Alexis Marina alexis@gebencommunication.com 330-519-6892 Two Labs Hires Anita Dopkosky as Vice President of Specialty Pharmacy Former specialty pharmacy leader at Walgreens to improve company’s market position in channel strategy and development COLUMBUS, Ohio (May 10, 2018) – Two Labs, an industry-leading pharma and life science services company, announced at Asembia’s […]

Aptose Exercises Early Option for CG-806 License From CrystalGenomics

May 8, 2018

SAN DIEGO and SEOUL, South Korea, May 07, 2018 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) and CrystalGenomics, Inc. (KOSDAQ:083790) today announced that Aptose exercised its option under the 2016 Option Agreement to exclusively license CG-806, a first-in-class, non-covalent pan-inhibitor of the Bruton’s tyrosine kinase (BTK) and FMS-like tyrosine kinase 3 (FLT3) from CrystalGenomics, […]

Amarantus Enters into Exclusive Option Agreement with Leipzig University to License IP Covering Alzheimer’s Blood Diagnostic LymPro Test 2.0 Blood Test vs. Amyloid PET

May 7, 2018

NEW YORK, May 04, 2018 (GLOBE NEWSWIRE) — Via OTC PR Wire — Amarantus Bioscience Holdings, Inc. (OTC Pink:AMBS) (the “Company” or AMBS), a US-based JLABS-alumnus biotechnology holding company, developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, today announced that it has entered into an exclusive option agreement with […]

FEEDBACK